{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:04:23Z","timestamp":1758672263106,"version":"3.44.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Korea Food & Drug Administration and Korean Health Technology R&D Project","award":["10172KFDA306"],"award-info":[{"award-number":["10172KFDA306"]}]},{"name":"Ministry of Health and Welfare","award":["HI13C0826"],"award-info":[{"award-number":["HI13C0826"]}]},{"DOI":"10.13039\/501100003624","name":"Ministry of Agriculture, Food and Rural Affairs","doi-asserted-by":"crossref","award":["MAFRA; 716002-7"],"award-info":[{"award-number":["MAFRA; 716002-7"]}],"id":[{"id":"10.13039\/501100003624","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.virol.2017.01.021","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T05:48:14Z","timestamp":1485841694000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine"],"prefix":"10.1016","volume":"504","author":[{"given":"Yun Ha","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo Han","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baik Lin","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2017.01.021_bib1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200868110-00002","article-title":"Cell-based influenza vaccines: Progress to date","volume":"68","author":"Audsley","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2017.01.021_bib2","first-page":"21","article-title":"Developing cell culture-derived pandemic vaccines","volume":"12","author":"Barrett","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.virol.2017.01.021_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/infdis\/jis641","article-title":"Localized mucosal response to intranasal live attenuated influenza vaccine in adults","volume":"207","author":"Barria","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2017.01.021_bib4","first-page":"745","article-title":"Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent","volume":"23","author":"Belshe","year":"2003","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.virol.2017.01.021_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0264-410X(99)00183-8","article-title":"Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children","volume":"18","author":"Boyce","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib6","unstructured":"Centers for Disease, C., Prevention, 2012. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR. Morbidity and mortality weekly report 61, pp. 613\u2013618"},{"key":"10.1016\/j.virol.2017.01.021_bib7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/infdis\/jiq144","article-title":"Comparison of a Live Attenuated 2009 H1N1 Vaccine with Seasonal Influenza Vaccines against 2009 Pandemic H1N1 Virus Infection in Mice and Ferrets","volume":"203","author":"Chen","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2017.01.021_bib8","doi-asserted-by":"crossref","first-page":"14802","DOI":"10.1073\/pnas.0905912106","article-title":"Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production","volume":"106","author":"Chu","year":"2009","journal-title":"P Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2017.01.021_bib9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.vaccine.2009.01.116","article-title":"A phase I clinical trial of a per.C6 (R) cell grown influenza H7 virus vaccine","volume":"27","author":"Cox","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib10","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1016\/j.vaccine.2006.06.023","article-title":"Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential","volume":"24","author":"Desheva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib11","doi-asserted-by":"crossref","first-page":"e1000409","DOI":"10.1371\/journal.ppat.1000409","article-title":"Immunogenicity and Protective Efficacy of a Live Attenuated H5N1 Vaccine in Nonhuman Primates","volume":"5","author":"Fan","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2017.01.021_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/fmb.10.161","article-title":"Safety of MDCK cell culture-based influenza vaccines","volume":"6","author":"Gregersen","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.virol.2017.01.021_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.vaccine.2008.11.003","article-title":"Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial","volume":"27","author":"Groth","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib14","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2017.01.021_bib15","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1016\/j.vaccine.2010.03.005","article-title":"Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells","volume":"28","author":"Hussain","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib16","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1128\/JVI.07149-11","article-title":"Cold-Adapted Pandemic 2009 H1N1 Influenza Virus Live Vaccine Elicits Cross-Reactive Immune Responses against Seasonal and H5 Influenza A Viruses","volume":"86","author":"Jang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2017.01.021_bib17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.vaccine.2016.01.053","article-title":"Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain","volume":"34","author":"Jang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib18","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.vaccine.2013.05.080","article-title":"Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines","volume":"31","author":"Jang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.vaccine.2012.12.072","article-title":"Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets","volume":"31","author":"Jang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.vaccine.2013.12.002","article-title":"Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A\/X-31 and B\/Lee\/40 donor strains","volume":"32","author":"Jang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3858\/emm.2010.42.2.013","article-title":"Reverse genetic platform for inactivated and live-attenuated influenza vaccine","volume":"42","author":"Jung","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.virol.2017.01.021_bib22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0042-6822(75)90284-6","article-title":"Activation of influenza A viruses by trypsin treatment","volume":"68","author":"Klenk","year":"1975","journal-title":"Virology"},{"key":"10.1016\/j.virol.2017.01.021_bib23","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.vaccine.2005.10.051","article-title":"Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus","volume":"24","author":"Lee","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tim.2011.12.002","article-title":"A cell-based backup to speed up pandemic influenza vaccine production","volume":"20","author":"Lee","year":"2012","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2017.01.021_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2016.01.022","article-title":"Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin","volume":"491","author":"Lee","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.virol.2017.01.021_bib26","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1016\/j.vaccine.2009.06.024","article-title":"Use of MDCK cells for production of live attenuated influenza vaccine","volume":"27","author":"Liu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib27","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1542\/peds.2008-1035","article-title":"Impact of the 2004\u20132005 influenza vaccine shortage on pediatric practice: a national survey","volume":"123","author":"McQuillan","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.virol.2017.01.021_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.NAJ.0000361490.52718.cf","article-title":"Influenza vaccination with a live attenuated vaccine The role of the pediatric nurse in immunization compliance","volume":"109","author":"Michael","year":"2009","journal-title":"Am. J. Nurs."},{"key":"10.1016\/j.virol.2017.01.021_bib29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1086\/605506","article-title":"Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity","volume":"200","author":"Reisinger","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2017.01.021_bib30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/303706a0","article-title":"Evidence for host-cell selection of influenza-virus antigenic variants","volume":"303","author":"Schild","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.virol.2017.01.021_bib31","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1128\/JVI.01373-09","article-title":"The polymerase acidic protein gene of influenza A virus contributes to pathogenicity in a mouse model","volume":"83","author":"Song","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2017.01.021_bib32","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1371\/journal.pmed.0030360","article-title":"Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets","volume":"3","author":"Suguitan","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.virol.2017.01.021_bib33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/605505","article-title":"Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture","volume":"200","author":"Szymczakiewicz-Multanowska","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2017.01.021_bib34","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2017.01.021_bib35","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59 (R)-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2017.01.021_bib36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.vaccine.2010.11.026","article-title":"Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in Mice and Ferrets","volume":"29","author":"Yang","year":"2011","journal-title":"Vaccine"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682217300302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682217300302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:39:46Z","timestamp":1758587986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682217300302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":36,"alternative-id":["S0042682217300302"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2017.01.021","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2017.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}